Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab

• Ian D. Pavord,
• Roland Buhl,
• Monica Kraft,
• Charlene M. Prazma,
• Robert G. Price,
• Peter H. Howarth,
• Steven W. Yancey

Affiliations

Ian D. Pavord

Respiratory Medicine Unit and Oxford Respiratory National Institute for Health Research Biomedical Research Centre, Nuffield Dept of Medicine, Oxford, UK

Roland Buhl

Pulmonary Dept, Johannes Gutenberg University of Mainz, Mainz, Germany

Monica Kraft

Dept of Medicine, University of Arizona, Tucson, AZ, USA

Charlene M. Prazma

Global Respiratory Franchise, GSK, Research Triangle Park, NC, USA

Robert G. Price

Biostatistics, GSK, Stevenage, Hertfordshire, UK

Peter H. Howarth

Respiratory Medical Franchise, GSK, Brentford, UK

Steven W. Yancey

Respiratory Therapeutic Area, GSK, Research Triangle Park, NC, USA